We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to GoodRx (GDRX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
In its upcoming report, GoodRx Holdings, Inc. (GDRX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.09 per share, reflecting an increase of 28.6% compared to the same period last year. Revenues are forecasted to be $196.2 million, representing a year-over-year increase of 6.6%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some GoodRx metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Revenue- Prescription transactions' to come in at $143.98 million. The estimate points to a change of +6.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenue- Other' should come in at $4.86 million. The estimate indicates a change of +8% from the prior-year quarter.
The consensus estimate for 'Revenue- Subscription' stands at $22.82 million. The estimate indicates a change of -5.3% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Pharma Manufacturer Solutions' reaching $23.21 million. The estimate indicates a change of +13.8% from the prior-year quarter.
Over the past month, shares of GoodRx have returned +2.9% versus the Zacks S&P 500 composite's -1.6% change. Currently, GDRX carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to GoodRx (GDRX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
In its upcoming report, GoodRx Holdings, Inc. (GDRX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.09 per share, reflecting an increase of 28.6% compared to the same period last year. Revenues are forecasted to be $196.2 million, representing a year-over-year increase of 6.6%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some GoodRx metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Revenue- Prescription transactions' to come in at $143.98 million. The estimate points to a change of +6.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenue- Other' should come in at $4.86 million. The estimate indicates a change of +8% from the prior-year quarter.
The consensus estimate for 'Revenue- Subscription' stands at $22.82 million. The estimate indicates a change of -5.3% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Pharma Manufacturer Solutions' reaching $23.21 million. The estimate indicates a change of +13.8% from the prior-year quarter.
View all Key Company Metrics for GoodRx here>>>
Over the past month, shares of GoodRx have returned +2.9% versus the Zacks S&P 500 composite's -1.6% change. Currently, GDRX carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>